Navigation Links
FDA Approved Nerve-Stimulation Therapy Now Available In New York

Vagus Nerve Stimulation therapy is a FDA approved long-term treatment regime for patients with treatment resistant depression (TRD). // This form of therapy is now being offered to patients at NewYork-Presbyterian Hospital/Columbia University Medical Center.

The treatment is now the first treatment specifically approved for TRD in patients over 18 years of age in whom antidepressant therapy has been unsuccessful atleast in four or more of the depressive episodes.

The treatment is instituted with the help of a small pacemaker-like device implanted in the chest area. The device sends mild pulses to the brain through the vagus nerve in the neck. A generator that runs under the skin to the left vagus nerve powers the device through a thin insulated wire.

The vagus nerve is one of the 12 cranial nerves and serves as the body’s information highway connecting the brain to many major organs. Several studies have shown that VNS Therapy may modulate neurotransmitters such as serotonin and norepinephrine thought to be involved in mood regulation.

Major depressive disorder is one of the most prevalent and serious illnesses in the U.S., affecting nearly 19 million Americans every year and more than 4 million people do not respond to conventional treatment such as psychotherapy, antidepressant medications, and even electroconvulsive therapy.

Nearly half of patients with an average of 25 years of major depressive disorder and multiple treatment trials realized some clinical benefit; one-third of patients had at least a 50 percent improvement in their depression; and one out of six was depression-free after treatment with VNS Therapy. Patients also reported significant improvements in quality-of-life areas, such as vitality, mental health, emotional well-being, and social functioning.

The new form of treatment is an important development in people with depression who need safe and effective therapeutic options. Several studie s have revealed the sustained beneficial efforts of the therapy over a considerable length of time. In addition, is it associated with better patient compliance and fewer side effects
'"/>




Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug To Treat Migraine
3. New FDA Approved Drug NATRECOR For Heart Failure Patients
4. New Oral Rinse For Gingivitis Approved By FDA
5. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
6. AIDS Generic Drugs Approved by FDA for Sale in US
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: